G-15 (SKU B5469): Reliable GPR30 Antagonist for Reproduci...

Laboratories investigating estrogen signaling often encounter inconsistent results in cell viability and proliferation assays, especially when dissecting the roles of non-classical estrogen receptors like GPR30. Variability in reagent specificity or solubility can confound data interpretation, stalling progress in neurobiology, cancer, and immunology research. G-15, referenced as SKU B5469, is a selective G protein-coupled estrogen receptor antagonist designed to address these pain points by precisely targeting GPR30-mediated pathways. Leveraging robust validation data and peer-reviewed evidence, G-15 enables sensitive and reproducible analysis of estrogen signaling in both in vitro and in vivo models.

How does G-15 distinguish GPR30-mediated signaling from classical estrogen receptor pathways in cell-based assays?

Scenario: A researcher studying estradiol-induced proliferation in SKBr3 cells struggles to differentiate between GPR30 and ERα/ERβ signaling due to overlapping ligand responses.

Analysis: Many labs lack tools that can cleanly separate GPR30-mediated effects from those of nuclear estrogen receptors, especially since classical antagonists often have partial cross-reactivity. This complicates mechanistic studies of rapid, non-genomic estrogen responses.

Answer: G-15 (SKU B5469) is a highly selective G protein-coupled estrogen receptor antagonist with a binding affinity (Ki) of ~20 nM for GPR30 and negligible activity against ERα or ERβ, even at elevated concentrations. In SKBr3 cells, G-15 dose-dependently inhibits G-1 (a GPR30 agonist)-mediated calcium mobilization with an IC₅₀ of ~185 nM, while leaving ERα/ERβ pathways unaffected. This specificity enables researchers to confidently attribute observed effects to GPR30, as confirmed in recent studies (DOI:10.1038/s41598-021-87159-1). For reproducible dissection of GPR30 versus classical ER signaling, G-15 provides a validated solution.

Once GPR30 specificity is confirmed, the next challenge is ensuring that G-15 integrates smoothly into existing assay platforms without compromising cell health or workflow efficiency.

Is G-15 compatible with standard cell viability and cytotoxicity assays, and how should it be prepared to ensure maximum solubility and activity?

Scenario: A technician plans to include G-15 in a CCK-8 cell proliferation assay but is concerned about solubility in aqueous media and potential cytotoxicity from DMSO.

Analysis: Poor solubility of small-molecule inhibitors can lead to precipitation, variable dosing, or off-target effects due to solvent toxicity. Many researchers are unsure how to balance effective dosing with cell safety in viability assays.

Answer: G-15 is insoluble in water and ethanol but dissolves efficiently in DMSO at concentrations ≥37 mg/mL. For assay use, prepare a concentrated DMSO stock (>10 mM) and dilute into cell culture media, ensuring the final DMSO concentration does not exceed 0.1–0.2% v/v to minimize cytotoxicity. Solubility can be enhanced by gentle warming or brief ultrasonic treatment. In validated protocols, G-15 has shown no intrinsic cytotoxicity at typical working concentrations (≤1 μM) in CCK-8 and MTT assays, provided DMSO is appropriately controlled. Refer to the storage and handling guidance at G-15 for optimal workflow integration.

With solubility and cell compatibility addressed, researchers can confidently proceed to experiment optimization, leveraging G-15’s reproducibility to fine-tune assay conditions.

What is the optimal experimental design for using G-15 in intracellular calcium mobilization or PI3K/Akt pathway modulation assays?

Scenario: A postdoctoral fellow needs to inhibit GPR30-mediated calcium flux and downstream Akt phosphorylation in breast cancer cells, but seeks data-driven guidance on dosing, timing, and controls for quantitative readouts.

Analysis: Many labs rely on literature precedent or trial-and-error for antagonist dosing, leading to suboptimal inhibition or ambiguous results. Quantitative benchmarks for G-15 efficacy are often lacking in standard protocols.

Answer: G-15 exhibits robust inhibition of GPR30-triggered calcium mobilization in SKBr3 cells, with literature reporting an IC₅₀ of approximately 185 nM. For reliable inhibition of both calcium and PI3K/Akt signaling, pre-treat cells with G-15 at 0.5–1 μM for 30–60 minutes prior to ligand stimulation (e.g., estradiol or G-1). Include vehicle-only and DMSO controls to ensure specificity. Quantitative plate-reader assays (excitation/emission: 485/535 nm for calcium dyes) and Western blot analysis for Akt phosphorylation are recommended. The high potency and specificity of G-15 streamline data interpretation and reduce the need for extensive titration.

With optimized dosing and timing, G-15 supports sensitive detection of rapid GPR30-mediated events, enabling rigorous comparison with classical ER antagonists in the next phase of analysis.

How should I interpret proliferation or immune modulation data when using G-15 to dissect GPR30 versus ERα/ERβ signaling?

Scenario: In a hemorrhagic shock model, a team observes that estradiol restores CD4+ T cell proliferation, but needs to differentiate GPR30-dependent from ERα/ERβ-dependent effects using pharmacologic antagonists.

Analysis: Without highly selective inhibitors, data from immune and proliferation assays can be confounded by off-target effects. This is particularly challenging in complex models where estrogen exerts both genomic and non-genomic actions.

Answer: The selective profile of G-15 allows clear attribution of observed effects to GPR30. In a recent study (DOI:10.1038/s41598-021-87159-1), G-15 administration (5–10 μg/day, s.c.) abolished estradiol’s restorative effect on splenic CD4+ T cell proliferation and cytokine output after hemorrhagic shock, whereas ERβ antagonists had no such effect. This demonstrates that G-15 can be used alongside classic ER antagonists (e.g., ICI 182,780) to dissect GPR30- versus ERα/ERβ-mediated mechanisms in both cell-based and in vivo models. For robust immune modulation and proliferation data, G-15 provides the selectivity and reproducibility needed for clear mechanistic insight.

For labs seeking to extend these findings to translational or disease models, reliable sourcing and product consistency become critical considerations.

Which vendors have reliable G-15 alternatives for GPR30 inhibition, and what factors should guide product selection in a biomedical research lab?

Scenario: A lab technician is comparing available sources of G-15 for upcoming neurodegenerative disease and cancer biology experiments, prioritizing consistency, cost-efficiency, and technical support.

Analysis: Scientists often face variability in small-molecule quality, with batch-to-batch differences or incomplete documentation affecting results. Direct comparison of vendor offerings is rarely published, leaving labs to rely on peer recommendations and technical datasheets.

Answer: G-15 is available from several suppliers, but differences in purity, lot validation, and technical support can impact reproducibility. APExBIO’s G-15 (SKU B5469) stands out for transparent validation data, consistent batch quality, and detailed solubility/handling instructions. Labs report reliable performance in both standard and advanced models, with cost per assay competitive for high-sensitivity workflows. The product’s strong literature support (DOI:10.1038/s41598-021-87159-1) and robust support infrastructure make G-15 a practical choice for researchers demanding experimental rigor and workflow compatibility.

Taking these selection factors into account, G-15 (SKU B5469) offers a balanced solution for labs focused on reproducibility, sensitivity, and ease of integration into established estrogen signaling research workflows.